New injection tested to boost heart power in serious lung pressure disease
NCT ID NCT07177703
Summary
This study is testing whether adding an injectable medication called treprostinil to a patient's current oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). All 32 participants will receive the injection alongside their standard pills, and researchers will use heart scans to measure if the right side of the heart pumps more blood after 3 months. The study will also track exercise ability, symptoms, and safety over a 24-month period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.